The IBRI fills a major research gap by connecting academic discovery and industry development, and public and private enterprise to improve human health.
Indiana ranks #9 on the list of states with the highest rate of diabetes, according to the Robert Wood Johnson Foundation. And, Indiana is ranked toward the bottom of the list (#41) for overall health, according to United Health Foundation’s America’s Health Rankings.
This is why both our mission and vision focus on the need to improve health. We will do that by better leveraging the life sciences resources in the Indianapolis area and beyond.
In 2012, Indiana state, civic, corporate and academic leaders called for creating an independent applied research institute to bridge industry and academic research. The goal is to capture and accelerate game-changing, outcome-driven research through the attraction and retention of internationally recognized talent to the Indiana Biosciences Research Institute (IBRI) and the state.
Founders of the IBRI were the State of Indiana, Eli Lilly and Company, Eli Lilly and Company Foundation, Lilly Endowment, Roche Diagnostics, Corteva Agriscience (formerly Dow AgroSciences), Indiana University Health, Indiana University School of Medicine, Cook Medical and BioCrossroads.
Founded in 2013, the IBRI is an independent, nonprofit discovery science and applied research institute targeting diabetes, cardiometabolic disease and poor nutrition. Inspired by Indiana’s life sciences companies, research universities, government and community organizations, the IBRI’s vision is to build a world-class organization of researchers, innovators and business leaders to catalyze activities across Indiana’s life sciences community, resulting in improved health for Indiana residents and beyond.
Over the next five years, the IBRI will continue to focus on its mission to become the leading independent, industry-inspired applied research institute in the discovery and development of innovative solutions to improve health, targeting diabetes, cardiometabolic disease and poor nutrition.
The IBRI’s labs and offices moved into the 16 Tech Innovation District, where the IBRI is the anchor tenant in Innovation Building 1, in September 2020. The IBRI's more than 40 full-time scientific and administrative employees enjoy 68,000 square feet of office, innovation, collaboration and lab space.
The IBRI was initially funded with $50 million provided by the state of Indiana, Lilly Endowment, Eli Lilly and Company, Roche Diagnostics, Dow AgroSciences, IU Health and Indiana University. In 2016, the institute received $88.5 million in funding commitments from Lilly Endowment, Eli Lilly and Company Foundation and Cook Medical. In 2017, the institute received an additional $20 million commitment from the State of Indiana.
The IBRI is looking to expand its partnerships with life sciences and IT companies and philanthropic organizations worldwide to increase the potential for research, discovery, translation and collaboration. For more information about donation and philanthropic opportunities, please visit http://www.indianabiosciences.org/giving/
The IBRI’s Values
- Collaborative – We cannot do research alone; this is a team sport and a long game; the IBRI exists to enhance the robust life sciences ecosystem by bridging industry and academic research.
- Teamwork – We work together as one team, both within and across our operations, and externally with our partners and stakeholders.
- Innovative – We are focused on game-changing research to help solve the most persistent health problems and challenges.
- Integrity – We do the right thing by adhering to the highest ethical standards and being honest, respectful, transparent, responsible, and accountable.
- Inclusive – We operate in a diverse ecosystem of colleagues, partners, stakeholders, and patients where we respect diversity in people and in ideas.
The IBRI’s Research Areas
IBRI Diabetes Center (IDC)
Dr. Bob Considine and Dr. Decio Eizirik are co-leading their team to study the molecular basis of diabetes and its complications. This center also is home to the Lilly Diabetes Center of Excellence, a collaboration with Eli Lilly and Company and Indiana University School of Medicine.
Applied Data Sciences Center (ADSC)
Dr. Dan Robertson and his team are making vast amounts of health data accessible for analysis by industry and academic partners to better identify and predict human diseases.
Pharmaceutical Biotechnology Center (PBC)
Dr. Vidadi Yusibov and his team are focusing on human health concerns through the development and manufacturing of therapeutic antibodies and vaccines.
Dr. Michael Pugia and his team are developing state-of-the art technology platforms for bioanalytical applications in life sciences. These efforts support the IBRI’s development of new standards of patient care.
The Board of Directors supervises the IBRI management structure. Members include a representative of the state of Indiana and other high-level members representing the life sciences industry, research institutions and state universities.